Key Points Investors continued to be positive on the pharmaceutical giant following a deal reached with the government. Among other benefits, it will have a reprieve from potential tariffs on its industry. 10 stocks we like better than Pfizer › Still basking in the glow of a likely advantageous deal it signed with the government the previous day, Pfizer's (NYSE: PFE) stock was extremely healthy on Hump Day. That positive sentiment was boosted by a positive analyst take, to the point where Pfizer's ...

Can you just walk us through the logic and ultimately the impact of this. Yeah, sure. I mean, the logic is pretty straightforward.Everybody believes that the US is paying so much more for medicines than the rest of the world is, and even the companies admit that. Of course they say that a lot of this is because a lot of the innovation happens in the US. So we're waiting to see how the US can actually implement this.And of course, we have this letter now from President Trump, which has got four elements in i ...

Core Points - President Trump signed an executive order aimed at reducing prescription drug prices by up to 90%, targeting pharmaceutical companies and middlemen [1][2] - The order revives the "most favored nation" policy, pushing foreign countries to share more of the R&D costs that the US has been shouldering [2] - The US pays the highest prices for prescription drugs, often nearly three times more than other developed nations [4] Company Impact - Shares of Cigna fell nearly 6% and CVS Health dropped over 3% following the announcement, indicating market concern over the executive order's implications [3][11] - Major US drugmakers initially saw stock declines but later rebounded as analysts suggested the order would be difficult to implement [12] - Merck, Pfizer, Gilead, and Eli Lilly experienced stock increases of 5.9%, 3.6%, 7.1%, and 2.9% respectively, reflecting investor optimism about their resilience against the order [12] Regulatory Actions - The order directs the US Trade Representative and Commerce Secretary to address unreasonable foreign drug pricing policies [6] - Health and Human Services Secretary will set targets for price reductions and initiate negotiations with industry leaders after 30 days [6][7] - The Federal Trade Commission is urged to enhance enforcement against anti-competitive practices by drugmakers [13]